About Pacira
Pacira is a publicly listed company based in Parsippany Troy Hills (United States) founded in 2006. Injectable non-opioid products for post-surgical pain control are developed. Pacira has raised $85 million across 3 funding rounds from investors including Orbimed, Oxford Finance and HBM Healthcare Investments. The company has 790 employees. Pacira has completed 3 acquisitions, including Flexion Therapeutics, GQ Bio and Myoscience. Its website pacira.com draws about 39 thousand monthly visits. Pacira offers products and services including EXPAREL, iovera°, and ZILRETTA. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Pacira BioSciences, Inc. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Pacira was founded in 2006 and is based in Parsippany Troy Hills, United States. Injectable non-opioid pharmaceuticals for postsurgical pain management are developed, with operations centered in the healthcare sector. The lead product, EXPAREL, consists of a bupivacaine liposome injectable suspension. DepoCyt, a sustained-release liposomal cytarabine formulation, is utilized for intrathecal treatment of lymphomatous meningitis as a lymphoma complication. The domain pacira.com is maintained.
- Headquarters Parsippany Troy Hills, United States
- Employees 790
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website pacira.com
- Social LinkedIn Instagram YouTube
- Legal Name Pacira Biosciences, Inc.
- Annual Revenue$726.41 M (USD)3.63as on Dec 31, 2025
- Net Profit$7.03 M (USD)as on Dec 31, 2025
- EBITDA$119.13 M (USD)-32.45as on Dec 31, 2025
- Total Equity Funding$85M (USD)
in 3 rounds
- Latest Funding Round$300M (USD), Post-IPO
Mar 2017
- InvestorsOrbimed
& 4 more
- Employee Count790
- Investments & AcquisitionsFlexion Therapeutics
& 2 more
Products & Services of Pacira
Pacira offers a comprehensive portfolio of products and services, including EXPAREL, iovera°, and ZILRETTA.
Injectable suspension for managing postsurgical pain effectively.
Cold therapy device for treating acute and chronic pain.
Extended-release injectable for knee osteoarthritis pain relief.
Apps and channels of Pacira
its YouTube channel Pacira BioSciences, Inc. has 18 subscribers and 17 videos.
Videos from Pacira
The most watched videos on Pacira's YouTube channel, Pacira BioSciences, Inc. (18 subscribers). Click a video to play it here.
More on Pacira BioSciences, Inc..
Funding Insights of Pacira
Pacira has successfully raised a total of $85M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $300 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $85M
- Total Rounds 3
- Last Round Post-IPO — $300M
- First Round $85M
(Nov 2008)
- Investors Count 5
All 3 funding rounds of Pacira with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2017 | $300M | Post-IPO | – | – | – |
| May 2012 | $27.5M | Debt – Conventional | – | – | |
| Nov 2008 | $85M | Series A | – | MPM Capital, HBM Healthcare Investments | – |
5 investors in total: 5 institutional.
Investors in Pacira
Pacira has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Oxford Finance and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Biomedical investment financing and active management services. | sanderling.com | |||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com |
Investor details for Pacira
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pacira
283 people are tracked at Pacira (147 in leadership, 10 in board & advisors, 126 in team); the tracked headcount is 790.
| Name | Role | Group |
|---|---|---|
Tyler Jones | Area Director Of Sales-west | Leadership |
Bryan Darge | Associate Director Market Access & Reimbursement | Leadership |
Sara Ghazaii Marino | Executive Director, Head Of Corporate Communications | Leadership |
Leanna B. | Director, Sales Operations | Leadership |
Susan Mesco | Vice President Investor Relations | Leadership |
Rosanne Atencio | Executive Director | Leadership |
Steven Savage | Associate Director, Corporate Accounting | Leadership |
Jonathan Slonin | Chief Medical Officer | Leadership |
Maksim N. | Executive Director Of Corporate And Business Development | Leadership |
Peter Hefti Cma, Cpa | Director - Science Center Campus Controller | Leadership |
Jeremy Grubb | Regional Business Director | Leadership |
Jillian Mangiro Phr | Senior Director, HR Business Partner | Leadership |
Alex Celius | Director, Compliance | Leadership |
Ebenezer Egyepong | Associate Director | Leadership |
Scott Daul | Senior Director Of Market Access - Reimbursement | Leadership |
David Cochran | Director IT Project Management | Leadership |
Chad Brightwell | Regional Sales Director | Leadership |
Jared Ham Pharmd, Bcps, Bcccp | Medical Science Liaison, Director | Leadership |
Stan Dysart M.D., Mba, Faaos | Vice President Medical Affairs, Orthopaedics | Leadership |
William L. Lanzer | Sr Director Medical Affairs - Orthopedic Specialty Group | Leadership |
263 more people are available in the full profile.
Complete people profiles for Pacira
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Pacira
Pacira is a publicly listed company on the NASDAQ with ticker symbol PCRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Feb 2011
- Listed onNASDAQ: PCRX
- Listed entityPacira BioSciences, Inc.
- Exchange sectorHealth technology
- ISINUS6951271005
- Share price$36.31 (-0.11% on the day) · 2026-10-13
- Market capitalisation$1.45B
- Price to earnings104.6
- EPS (diluted, trailing year)$0.35
- Volume (last session)2,221,886
Financials of Pacira
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $726.4M | $7.0M | $119.1M |
| 2024 | $701.0M | -$99.6M | $176.4M |
| 2023 | $675.0M | $42.0M | $162.9M |
| 2022 | $666.8M | $15.9M | $162.4M |
| 2021 | $541.5M | $42.0M | $161.4M |
Detailed financial statements for Pacira
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pacira
Pacira has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Flexion Therapeutics, GQ Bio and Myoscience.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of gene therapies for orthopedic treatment | gq-biotx.com | Hamburg, Germany | 2012 | Feb 2025 | $32M | |
Developer of therapies for the treatment of musculoskeletal disorders | flexiontherapeutics.com | Woburn, United States | 2007 | Oct 2021 | $425M | |
Technology-driven dermatological products are developed and commercialized. | myoscience.com | Redwood, United States | 2005 | Mar 2019 | $120M |
Complete acquisition details for Pacira
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Pacira
7 dated milestones of Pacira across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Pacira is founded.
- Funding First funding round of $85.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $300.0M.
- Acquisition Acquires Myoscience.
- Acquisition Acquires Flexion Therapeutics.
- Acquisition Acquires GQ Bio.
Competitors of Pacira
Pacira has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Pacira
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pacira
The website of Pacira (pacira.com) receives about 39.1K visits a month and ranks #1,306,031 among all websites worldwide, #1,681 in Biotechnology and Pharmaceuticals.
- Monthly visits39.1K
▲ 104.4% vs previous month
- Unique visitors8.2K
per month
- Global rank#1,306,031
among all websites
- Category rank#1,681
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit2.1
- Average visit46 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Pacira. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| takeda.com | 100% | 620.1K | #93,966 | View details | |
| salix.com | 91% | 15.6K | #1,433,848 | View details | |
| arenapharm.com | 89% | View details | |||
| progenics.com | 83% | View details | |||
| amagpharma.com | 81% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Pacira
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Pacira (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pacira
Complete news archive for Pacira
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pacira
Pacira was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Pacira is headquartered in Parsippany Troy Hills, United States. It is registered at Parsippany Troy Hills, New Jersey, United States.
Pacira is a funded company, having raised a total of $85M across 3 funding rounds to date. The company's 1st funding round was a Series A of $85M, raised on Nov 2008.
Pacira has 790 employees.
Annual revenue of Pacira is $726.41M as on Dec 31, 2025.
Pacira was founded in 2006 and is based in Parsippany Troy Hills, United States. Injectable non-opioid pharmaceuticals for postsurgical pain management are developed, with operations centered in the healthcare sector. The lead product, EXPAREL, consists of a bupivacaine liposome injectable suspension. DepoCyt, a sustained-release liposomal cytarabine formulation, is utilized for intrathecal treatment of lymphomatous meningitis as a lymphoma complication. The domain pacira.com is maintained.
Pacira's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Pacira offers EXPAREL, iovera°, and ZILRETTA.
Yes, Pacira is publicly traded on NASDAQ under the ticker symbol PCRX.
Pacira has made 3 acquisitions, including Flexion Therapeutics, GQ Bio, and Myoscience.
Pacira has 5 investors. Key investors include Orbimed, Oxford Finance, HBM Healthcare Investments, Turmeric Acquisition Corp, and Sanderling Ventures.
Pacira operates through Pacira Biosciences, Inc..